Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension

Core Insights - Idorsia Ltd has launched a groundbreaking initiative called IMPACT-HTN in collaboration with Stanford Hypertension Center and Duke Heart Center to modernize the management of difficult-to-control hypertension [1][2][4] - The program aims to generate real-world evidence, standardize clinical decision-making, and develop AI-powered tools to improve patient outcomes [1][3][4] - TRYVIO™ (aprocitentan), a new treatment targeting a novel pathway in hypertension, is central to this initiative and has been included in recent clinical practice guidelines [6][16] Company Overview - Idorsia is focused on discovering, developing, and commercializing transformative medicines, with a commitment to improving patient outcomes beyond just medication [4][17] - The company is headquartered in Allschwil, Switzerland, and is listed on the SIX Swiss Exchange under the ticker symbol IDIA [18] Industry Context - Hypertension affects approximately 50% of adults in the US, posing significant health risks including cardiovascular events and premature mortality [2] - The IMPACT-HTN program addresses the challenges faced by patients with difficult-to-control hypertension, who often require multiple medications and face coordination issues [1][2][3] Program Details - The IMPACT-HTN initiative consists of three phases aimed at improving care for patients with difficult-to-control hypertension [1][3] - Key components of the program include a digital care algorithm, a personalized hypertension risk score, and a prospective early patient experience initiative [5]